- Robert F. Service
Science 07 Oct 2016:
Vol. 354, Issue 6308, pp. 26-28
DOI: 10.1126/science.354.6308.26
Robert F. Service
- Article
- Figures & Data
- Info & Metrics
- eLetters
You are currently viewing the summary.
View Full Text
Via AAAS ID
This article is available to AAAS members. If you are a AAAS Member use your via AAAS ID and password to log in. Not a member? Click here to join.
Via your Institution
Log in through your institution
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
Log in through your institution
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
- Join/Subscribe
- Purchase Article
- Activate Member Account
- Renew Subscription
- Recommend a subscription to your library
- Help for librarians
Free with registration
Science research is available free with registration one year after initial publication. To get your free access please visit our registration form.
Summary
P53 is a protein that plays a critical role in preventing cells with DNA damage or other cellular insults from turning cancerous. The protein is mutated in about half of all human cancers. When that happens p53 is unable to fold up into its normal 3D shape, which prevents it from latching onto DNA and sounding the cellular alarm in response to damage. Researchers have long tried to combat cancer by boosting the number of copies of healthy p53 in cells, and a number of drugs that do that remain in human trials. But none has yet made it to market. Now, researchers are making headway on a new approach, finding drugs that prop up mutated p53 and restore its proper shape so that it can once again bind DNA and signal for help. One such drug has already passed an initial human trial and others are on the way. If any succeed, they could change the landscape of cancer therapy and perhaps pave the way for other protein-rescuing drugs to combat protein-misfolding diseases such as Alzheimer’s and Parkinson’s.
Science
- Table of Contents
- Print Table of Contents
- Advertising (PDF)
- Classified (PDF)
- Masthead (PDF)
Article Tools
-
Email
-
Download Powerpoint
-
Print
-
Save to my folders
-
Alerts
Please log in to add an alert for this article.
-
Citation tools
Rescuing the guardian of the genome
New drugs combat cancer by propping up a mutated tumor-fighting protein.
Citation Manager Formats
- BibTeX
- Bookends
- EasyBib
- EndNote (tagged)
- EndNote 8 (xml)
- Medlars
- Mendeley
- Papers
- RefWorks Tagged
- Ref Manager
- RIS
- Zotero
-
Share
Rescuing the guardian of the genome
New drugs combat cancer by propping up a mutated tumor-fighting protein.
Permalink:
Related Content
Similar Articles in:
Citing Articles in:
Related Jobs from ScienceCareers
- Cell Biology
- Genetics
- Medicine, Diseases
- Molecular Biology
- Pharmacology, Toxicology
Science
11 November 2016
-
Feature
The lost norse
-
Technology Governance
Precaution and governance of emerging technologies
-
Genetic Engineering
Tinkering with evolution
-
SCI COMMUN
News at a glance
-
Epidemiology
Leprosy in red squirrels
-
Working Life
The problem with ‘alternative’
Table of Contents
